TERT and meningioma: Given the low frequency of TERT promotor mutations in meningiomas in general and in grade 1 lesions in particular, the current WHO classification recommends “consideration (of TERT sequencing) in clinically aggressive atypical meningiomas or those with borderline CNS WHO grade 2/3 features” [4].